Benzinga | Jul 20, 2021 07:06AM EDT

Lantern Pharma Announces Preclinical Data In Pancreatic Cancer With Drug Candidate LP-184; Data Showed LP-184 Demonstrated Over 90% Pancreatic Tumor Shrinkage In In-Vivo Mouse Models In Eight Weeks

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. Preclinical data demonstrated that the drug candidate, LP-184, demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. In comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8 week period.